AstraZeneca: Ultomiris Approved in the US for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder
March 26, 2024
March 26, 2024
WILMINGTON, Delaware, March 26 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on March 25, 2024:
ULTOMIRIS(R) (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1
The approval by the US Food and Drug Administration (FDA) was ba . . .
ULTOMIRIS(R) (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1
The approval by the US Food and Drug Administration (FDA) was ba . . .